{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 63,
  "pageCount": 120,
  "prevPage": 62,
  "nextPage": 64,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "FIH stands for first-in-human.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/63",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-63",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 1,
        "x": 0,
        "y": 0.76
      },
      "kind": "callout",
      "text": "Building on a track record of rapid clinical development and successful global commercialization of infectious disease vaccines",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c20ddcda-c36d-4f97-91dc-203bd4fea613",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.26,
        "x": 0.355,
        "y": 0.55
      },
      "kind": "image",
      "text": "BIONTECH + Pfizer",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd35207d-177c-43a9-be63-7532cb185fcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.215,
        "x": 0.38,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "COVID-19: COMIRNATY: globally leading franchise. Variant-adapted vaccine launch planned for 2H 2022",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c2e33cf-ea14-4a88-bdad-2e2f4804b0b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.285,
        "x": 0.048,
        "y": 0.455
      },
      "kind": "paragraph",
      "text": "Shingles: Potential first-in-class mRNA-based shingles vaccine with blockbuster potential. FIH Phase 1 trial 2H 2022",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bede467b-535f-40d0-a7e1-84027a355255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.23,
        "x": 0.723,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Influenza: Single-dose quadrivalent mRNA vaccine. Phase 1 data update expected in 2022",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bff7e1e8-723f-46a9-978a-cbf987b04de8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.048,
        "y": 0.105
      },
      "kind": "title",
      "text": "BioNTech and Pfizer global mRNA collaboration programs in infectious diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8476e4d2-7bd0-4f2a-b7c4-20ea9eb0ed33",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "721505c3-c88f-43a3-9a0d-b94fc464e291",
      "evidence": "paragraph/paragraph: Shingles: Potential first-in-class mRNA-based shingles vaccine with blockbuster potential. FIH Phase 1 trial 2H 2022",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 70,
      "from": 60,
      "beatId": "ad024950-7f4b-4056-b7c8-680591fc503c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Opportunity",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The presentation highlights the market opportunity in infectious diseases and oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}